Priority review for Roche’s Tecentriq/Abraxane combo

14th November 2018 Uncategorised 0

US regulators are undertaking a priority review of Roche’s Tecentriq in combination with Abraxane for the treatment of triple-negative breast cancer.

More: Priority review for Roche’s Tecentriq/Abraxane combo
Source: News